Colloidal bismuth pectin-containing quadruple therapy as the first-line treatment of Helicobacter pylori infection: A multicenter, randomized, double-blind, non-inferiority clinical trial.
Yong XieYi HuYin ZhuHong WangQi-Zhi WangYan-Qing LiJiang-Bin WangZhen-Yu ZhangDe-Kui ZhangXiao-Wei LiuNong Hua LuPublished in: Helicobacter (2023)
Both CBP and BPC quadruple therapy for 14 days provide high efficacy, good compliance, and safety in the first-line treatment of H. pylori in China.